STOCK TITAN
  1. Home
  2. News
  3. BEAT

HeartBeam Inc - BEAT STOCK NEWS

Welcome to our dedicated news page for HeartBeam (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on HeartBeam.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HeartBeam's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HeartBeam's position in the market.

News
HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on May 9, 2024, to discuss its first-quarter results, regulatory updates, ongoing initiatives, and 2024 milestones. CEO Branislav Vajdic, President Robert Eno, and Consulting CFO Richard Brounstein will lead the call. Investors can access the webcast or call in using the provided details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
conferences earnings
-
News
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
Rhea-AI Summary
HeartBeam, Inc. (BEAT) presents groundbreaking data at EHRA conference showcasing the efficacy of HeartBeam AI in detecting atrial flutter. The study reveals a 28% improvement over single-lead ECGs, aligning with 12-lead ECG performance standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) reports financial and operational results for Q4 and full year 2023, highlighting progress in clinical and regulatory milestones for the AIMIGo™ 3D VECG system. The company anticipates FDA clearance for the AIMIGo system by Q2 2024 and aims to launch AIMIGo by the end of 2024. Recent patents on core VECG technology and AI program developments enhance the company's intellectual property and diagnostic capabilities. Financially, R&D and G&A expenses increased, resulting in a net loss for Q4 and full year 2023. Cash and cash equivalents stood at $16.2 million as of December 31, 2023, supporting upcoming milestones and extending cash runway into early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
earnings
News
First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) has enrolled the first patients in the VALID-ECG pivotal study to evaluate the performance of their 12-lead ECG synthesis software for arrhythmia detection. The study aims to compare the synthesized ECG with a standard hospital-based ECG using quantitative and qualitative methodologies. AIMIGo, the technology behind the study, utilizes 3D VECG technology to capture signals in three projections and synthesize a 12-lead ECG. The study marks a significant advancement in cardiac monitoring technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
News
HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) secures two new patents for its core vectorelectrocardiography (VECG) technology, bringing the total to 14 US and 4 international patents. The innovative VECG technology collects 3D heart signals and converts them into a 12-lead ECG, enabling monitoring outside medical facilities with portable devices. CEO Branislav Vajdic emphasizes the strategic importance of protecting their product pipeline for revolutionizing cardiac care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.54%
Tags
none
-
News
HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time
Rhea-AI Summary
HeartBeam, Inc. (BEAT) will host a conference call on March 20, 2024, to discuss its Q4 and full-year 2023 results, along with regulatory updates and 2024 milestones. CEO Branislav Vajdic, President Robert Eno, and other key executives will lead the call. Investors can access the call and presentation via webcast or phone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences earnings
News
HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) appoints Mohammad Shokoohi-Yekta to lead program and industry pioneer Lance Myers as advisor. The company aims to transform cardiac care through personalized insights using AI and VECG technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
AI
-
News
HeartBeam Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) strengthens leadership with key appointments and publishes a landmark peer-reviewed article validating its technology. The company reported financial and operational results for Q3 2023, highlighting key achievements and ongoing clinical and regulatory progress for the HeartBeam AIMIGo™ VECG Device. The company also announced the appointment of new executives and board members, as well as significant progress towards key clinical and regulatory milestones. Financially, the company reported a total of approximately $19.2 million in cash and cash equivalents as of September 30, 2023, with a projected cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.63%
Tags
earnings
-
News
HeartBeam Announces Expansion of Its Scientific Advisory Board
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) announced the addition of leading cardiologists to its Scientific Advisory Board. The SAB will now include experts such as Dr. Peter J. Fitzgerald and Dr. C. Michael Gibson, among others. This move is expected to provide strategic insights for the company's credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, and to enhance its clinical and commercial efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
management
News
HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) has been granted a new patent for its novel 3D-vector electrocardiogram (VECG) platform, solidifying its position in the large global electrocardiogram patch market. This patent strengthens the company's intellectual property footprint and represents a significant step towards bringing its 12-lead extended wear patch to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
Stock BEAT logo
HeartBeam Inc

Nasdaq:BEAT

BEAT Rankings

#4688 Ranked by Market Cap
#4937 Ranked by Stock Gains
N/A Ranked by Dividends

BEAT Stock Data

47.39M
19.29M
28.17%
8.8%
0.61%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Santa Clara

About BEAT

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.